Medtech developer See All AI has closed a $33 million funding round aimed at accelerating the development and commercialization of its AI-based platform.
The Nashua, NH-based company’s platform creates detailed 3D models with 1-mm cross-sectional slices from as few as two intraoperative fluoroscopic images, See All AI said in a statement. The platform is designed to work with existing fluoroscopy units and requires no direct line of sight between the company’s proprietary visible light camera and the patient’s anatomy.
In addition to the platform, See All AI has developed the Track All visible light spectrum camera, a machine vision system that requires no markers, emitters, or direct line of sight to anatomy.
The platform and camera are not currently available for clinical use, and they have not yet been cleared by the U.S. Food and Drug Administration (FDA). The company said that it plans to apply for FDA clearance in 2025.
